

Astrid Fahrleitner-Pammer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5071951/astrid-fahrleitner-pammer-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59
papers

2,411
citations

24
h-index

49
g-index

66
ext. papers

2,869
ext. citations

4.9
avg, IF

4.57
L-index

#	Paper	IF	Citations
59	Usefulness of the trabecular bone score in maintenance dialysis patients : A single center observational study.. <i>Wiener Klinische Wochenschrift</i> , 2022 , 1	2.3	0
58	Morphometric parameters of muscle and bone in critically ill patients : Post hoc analysis of the VITdAL-ICU trial. <i>Wiener Klinische Wochenschrift</i> , 2021 , 133, 529-535	2.3	
57	Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture - results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS). <i>Bone</i> , 2021 , 142, 115071	4.7	6
56	Thirty years of hip fracture incidence in Austria: is the worst over?. <i>Osteoporosis International</i> , 2021 , 1	5.3	2
55	Efficacy of teriparatide compared with risedronate on FRAX-defined major osteoporotic fractures: results of the VERO clinical trial. <i>Osteoporosis International</i> , 2020 , 31, 1935-1942	5.3	7
54	SAT-LB71 Is Late Diagnosis of Postsurgical Hypoparathyroidism the Rule, Not the Exception?. <i>Journal of the Endocrine Society</i> , 2020 , 4,	0.4	78
53	Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial. <i>Calcified Tissue International</i> , 2020 , 106, 646-654	3.9	3
52	Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial. <i>Archives of Osteoporosis</i> , 2019 , 14, 10	2.9	4
51	Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. <i>Osteoporosis International</i> , 2019 , 30, 1855-1864	5.3	9
50	Prescreening for Osteoporosis With Quantitative Ultrasound in Postmenopausal White Women. <i>Journal of Ultrasound in Medicine</i> , 2019 , 38, 1553-1559	2.9	9
49	Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial. <i>Skeletal Radiology</i> , 2019 , 48, 1023-1032	2.7	10
48	Bone matrix hypermineralization associated with low bone turnover in a case of Nasu-Hakola disease. <i>Bone</i> , 2019 , 123, 48-55	4.7	4
47	Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 783-794	6.3	59
46	Bone-related Circulating MicroRNAs miR-29b-3p, miR-550a-3p, and miR-324-3p and their Association to Bone Microstructure and Histomorphometry. <i>Scientific Reports</i> , 2018 , 8, 4867	4.9	48
45	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2498-2509	5.6	51
44	Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 2230-2235	6.3	8
43	Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. <i>Lancet, The</i> , 2018 , 391, 230-240	4.0	244

42	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 513-523	18.1	419
41	Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. <i>Osteoporosis International</i> , 2017 , 28, 1149-1152	5.3	7
40	A New Murine Model of Chronic Kidney Disease-Mineral and Bone Disorder. <i>International Journal of Endocrinology</i> , 2017 , 2017, 1659071	2.7	3
39	Relationship between bone turnover and left ventricular function in primary hyperparathyroidism: The EPATH trial. <i>PLoS ONE</i> , 2017 , 12, e0173799	3.7	7
38	Plasma parathyroid hormone and cardiovascular disease in treatment-naive patients with primary hyperparathyroidism: The EPATH trial. <i>Journal of Clinical Hypertension</i> , 2017 , 19, 1173-1180	2.3	8
37	Effect of vitamin D3 on bone turnover markers in critical illness: post hoc analysis from the VITdAL-ICU study. <i>Osteoporosis International</i> , 2017 , 28, 3347-3354	5.3	8
36	Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial. <i>Bone</i> , 2017 , 105, 212-217	4.7	5
35	Factors associated with high 24-month persistence with denosumab: results of a real-world, non-interventional study of women with postmenopausal osteoporosis in Germany, Austria, Greece, and Belgium. <i>Archives of Osteoporosis</i> , 2017 , 12, 58	2.9	27
34	Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality. <i>Bone</i> , 2017 , 95, 41-46	4.7	36
33	Serum sclerostin levels in renal cell carcinoma patients with bone metastases. <i>Scientific Reports</i> , 2016 , 6, 33551	4.9	1
32	FRI0545 A Novel Feature Selection Algorithm Based on Bone Micro Architecture Analysis To Identify Osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 637.2-638	2.4	1
31	SAT0557 A Clinical Study To Examine Thresholds of Joint Space Width and Joint Space Area for Identification of Knee Osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 871.1-871	2.4	1
30	Plasma Parathyroid Hormone Is Independently Related to Nocturnal Blood Pressure in Hypertensive Patients: The Styrian Hypertension Study. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 543-50	2.3	7
29	Effects of vitamin D supplementation on glycated haemoglobin and fasting glucose levels in hypertensive patients: a randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2016 , 18, 1006-12	6.7	19
28	OP0306 Ten Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from The Freedom Extension Trial. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 173.2-174	2.4	
27	Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment. <i>Bone</i> , 2016 , 89, 16-24	4.7	18
26	Effects of Vitamin D Supplementation on Plasma Aldosterone and Renin-A Randomized Placebo-Controlled Trial. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 608-13	2.3	29
25	Interrelated aldosterone and parathyroid hormone mutually modify cardiovascular mortality risk. <i>International Journal of Cardiology</i> , 2015 , 184, 710-716	3.2	19

24	Effects of vitamin D on blood pressure and cardiovascular risk factors: a randomized controlled trial. <i>Hypertension</i> , 2015 , 65, 1195-201	8.5	118
23	Bone - a casualty of ICU survival?. <i>Critical Care</i> , 2015 , 19, 253	10.8	3
22	FGF23 in Acute and Chronic Illness. <i>Disease Markers</i> , 2015 , 2015, 358086	3.2	25
21	Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. <i>Osteoporosis International</i> , 2015 , 26, 2479-89	5.3	57
20	Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study. <i>Bone</i> , 2014 , 58, 48-54	4.7	118
19	Effects of teriparatide on cortical histomorphometric variables in postmenopausal women with or without prior alendronate treatment. <i>Bone</i> , 2014 , 59, 139-47	4.7	63
18	Current controversies in clinical management of postmenopausal osteoporosis. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014 , 122, 437-44	2.3	5
17	Incidence of ischemic type biliary lesions after liver transplantation using piggyback technique and retrograde reperfusion. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2013 , 45, 3-7	0.9	1
16	Aldosterone to renin ratio is associated with 24 hour ambulatory blood pressure in essential hypertensives: the Styrian Hypertension study. <i>European Heart Journal</i> , 2013 , 34, P5658-P5658	9.5	
15	Osteoporosis, weight gain and atypical fat accumulations - a typical feature not only for Cushing's, but also Madelung's disease: A case report. <i>Wiener Klinische Wochenschrift</i> , 2012 , 124, 188-92	2.3	3
14	The role of osteoprotegerin (OPG) receptor activator for nuclear factor kappa B ligand (RANKL) in cardiovascular pathology - a review. <i>Wiener Medizinische Wochenschrift</i> , 2011 , 161, 565-70	2.9	8
13	Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). <i>Osteoporosis International</i> , 2011 , 22, 2709-19	5.3	64
12	Vitamin D deficiency following Billroth II surgery - How much vitamin D is enough?: a case report. <i>Cases Journal</i> , 2010 , 3, 12		1
11	Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. <i>Osteoporosis International</i> , 2010 , 21, 2027-36	5.3	48
10	Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?. <i>Wiener Medizinische Wochenschrift</i> , 2010 , 160, 452-7	2.9	32
9	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2256-65	6.3	173
8	Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1335-44	6.3	44
7	The effect of RANKL and OPG on bone mineral density in pre-dialysis chronic renal failure. <i>Clinical Nephrology</i> , 2009 , 71, 652-9	2.1	11

6	Bone markers predict cardiovascular events in chronic kidney disease. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 1850-8	6.3	72
5	Calcium supply, bone mineral density and genetically defined lactose maldigestion in a cohort of elderly men. <i>Journal of Endocrinological Investigation</i> , 2007 , 30, 46-51	5.2	14
4	Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. <i>Bone</i> , 2007 , 41, 378-85	4.7	120
3	Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. <i>Osteoporosis International</i> , 2006 , 17, 693-703	5.3	65
2	Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3970-7	5.6	162
1	Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. <i>Wiener Klinische Wochenschrift</i> , 2003 , 115, 291-7	2.3	44